Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Axel Hauschild et al.|New England Journal of Medicine|2017Cited by 1.5k
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalitionBob T. Li, Yi‐Long Wu, Lola A. Fashoyin‐Aje et al.|Nature Medicine|2022Cited by 52
Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant MelanomaGeorgina V. Long, John M. Kirkwood, Axel Hauschild et al.|SKIN The Journal of Cutaneous Medicine|2018Cited by 1